<DOC>
	<DOCNO>NCT00518895</DOCNO>
	<brief_summary>This study perform prospectively determine whether dacarbazine plus Genasense significantly good dacarbazine plus placebo chemotherapy-naive patient advance melanoma low baseline LDH ( LDH le equal 0.8 time upper limit normal ) . LDH biomarker strongly associate improve outcome recent trial dacarbazine plus Genasense .</brief_summary>
	<brief_title>Trial Dacarbazine With Without Genasense Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm diagnosis melanoma Progressive disease surgically resectable , metastatic Stage IV Lownormal LDH , define ≤ 0.8 time upper limit normal No prior chemotherapy Measurable disease ECOG performance status ≤ 1 At least 4 week recovery effect major prior surgery therapy , include immunotherapy , radiation therapy , cytokine , biologic vaccine therapy Prior immunotherapy allow Adequate organ function Prior cytotoxic chemotherapy , include regional perfusion , prior Genasense treatment Primary ocular mucosal melanoma Boneonly metastatic disease History presence brain metastasis leptomeningeal disease Significant medical disease cancer Organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Advanced Melanoma</keyword>
	<keyword>Malignant Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Skin Cancer</keyword>
	<keyword>Genasense</keyword>
	<keyword>oblimersen</keyword>
	<keyword>antisense</keyword>
	<keyword>Bcl-2 antisense</keyword>
	<keyword>G3139</keyword>
	<keyword>dacarbazine</keyword>
</DOC>